Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue: 2018-2025

Historic Non-Current Deffered Revenue for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $74.1 million.

  • Bicycle Therapeutics' Non-Current Deffered Revenue fell 24.22% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 24.22%. This contributed to the annual value of $91.5 million for FY2024, which is 17.01% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Non-Current Deffered Revenue of $74.1 million as of Q3 2025, which was down 10.64% from $82.9 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Non-Current Deffered Revenue high stood at $115.1 million for Q2 2023, and its period low was $25.3 million during Q2 2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $94.0 million (2024), whereas its average is $94.3 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Non-Current Deffered Revenue skyrocketed by 165.87% in 2023 and then fell by 24.22% in 2025.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Non-Current Deffered Revenue stood at $52.1 million in 2021, then decreased by 20.38% to $41.5 million in 2022, then surged by 165.87% to $110.2 million in 2023, then fell by 17.01% to $91.5 million in 2024, then dropped by 24.22% to $74.1 million in 2025.
  • Its Non-Current Deffered Revenue was $74.1 million in Q3 2025, compared to $82.9 million in Q2 2025 and $82.2 million in Q1 2025.